Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00080886 · ClinicalTrials.gov registry record · Phase 2
Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma
A Phase 2 study, sponsored by University of Nebraska.
- Completed
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
NCT00080886 is a Phase 2 study that has completed, run by University of Nebraska. The registered enrollment target is 68 participants.
The verdict
NCT00080886, a Phase 2 study, has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as carmustine, cytarabine, etoposide, and melphalan, work in different ways to stop cancer cells from dividing so they stop growing or die. Combining rituximab and combination chemotherapy with autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining rituximab with combination chemotherapy followed by autologous hematopoietic stem cell transplantation in treating patients who have B-cell non-Hodgkin's lymphoma.
Interventions
- BIOLOGICAL rituximab
- DRUG etoposide
- DRUG melphalan
- DRUG carmustine
- DRUG cytarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2002-05-08 |
| Est. Completion | 2015-03-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00080886
The ClinicalTrials.gov registry entry for NCT00080886 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which rituximab is the first listed.
NCT00080886 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00080886 about?
NCT00080886 is a clinical study titled "Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma". RATIONALE: Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as carmustine, cytarabine, etoposide, and melphalan, work in different ways to stop cancer cel...
What is the current status of trial NCT00080886?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2002-05-08. Estimated completion is 2015-03-12.
What interventions are being tested in trial NCT00080886?
The interventions under investigation include: rituximab (BIOLOGICAL), etoposide (DRUG), melphalan (DRUG), carmustine (DRUG), cytarabine (DRUG).
Who is sponsoring clinical trial NCT00080886?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.